Loading stock data…
$217.77-1.21 (-0.55%)
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally.
STERIS plc in the Healthcare sector is trading at $217.77. Wall Street consensus targets $262.14 (7 analysts), implying a +20.4% move over the next 12 months. The stock is currently 19% below its 52-week high of $269.44, remaining 3.5% below its 200-day moving average. On fundamentals, Piotroski 9/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.49B↓ | $1.59B↑ | $1.50B↑ | $1.46B↑ | $1.39B |
| Gross Profit | $684.20M↓ | $697.10M↑ | $655.50M↑ | $645.90M↑ | $628.00M |
| Operating Income | $285.90M↓ | $316.50M↑ | $273.70M↑ | $268.00M↑ | $247.80M |
| Net Income | $200.10M↓ | $220.20M↑ | $192.80M↑ | $191.90M↑ | $177.40M |
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chem...
Academic risk and quality models computed from STE's own filings and price history, not from analyst opinion.
Strong on 9 of 9 fundamental-health tests covering profitability, leverage and operating efficiency.
Altman Z below 1.81, the financial-distress band. This measures balance-sheet stress, not share-price direction.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
GARCH(1,1) 30-day annualised forecast, below the current 25.9% reading.
Fama-French 5-factor market beta. The five factors explain 29% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.